JL1102EH - JL1102EH: Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial

Full author listing

Yasmin Karimi, MD,^1* Herve Ghesquieres, MD, PhD,² Wojciech Jurczak, MD, PhD,³ Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc,⁴ Michael Roost Clausen, MD, PhD,⁵ Pieternella Lugtenburg, MD, PhD,⁶ David Cunningham, MD, FRCP, FMedSci,⁷ Young Rok Do, MD, PhD,⁸ David John Lewis, MD,⁹ Robin Gasiorowski, MBBS, FRACP, FRCPA, PhD,¹⁰ Tae Min Kim, MD, PhD,¹¹ Marjolein van der Poel, MD, PhD,¹² Michelle Limei Poon, MBBS, MRCP,¹³ Tatyana Feldman, MD,¹⁴ Kim M. Linton, MBChB, PhD,¹⁵ Anna Sureda, MD, PhD,¹⁶ Martin Hutchings, MD, PhD,¹⁷ Mariana Cota Stirner, MD, PhD,¹⁸ Mariana Sacchi, MD,¹⁹ Catherine Thieblemont, MD, PhD²⁰

¹University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; ²Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France; ³MSC National Research Institute of Oncology, Kraków, Poland; ⁴Sir Charles Gairdner Hospital, Nedlands, Australia; ⁵Vejle Hospital, Vejle, Denmark; ⁶On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands; ⁷The Royal Marsden NHS Foundation Trust, Sutton, UK; ⁸Keimyung University Dongsan Medical Center, Daegu, Republic of Korea; ⁹University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK; ¹⁰Concord Hospital, University of Sydney, Sydney, Australia; ¹¹Seoul National University Hospital, Seoul, Republic of Korea; ¹²On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands; ¹³National University Hospital, Singapore; ¹⁴Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ, USA; ¹⁵The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK; ¹⁶Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; ¹⁷Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ¹⁸AbbVie, North Chicago, IL, USA; ¹⁹Genmab, Princeton, NJ, USA; ²⁰Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France

*Corresponding author.